

Alvin H Schmaier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4255710/publications.pdf>

Version: 2024-02-01

215
papers

9,627
citations

31902

53
h-index

40881

93
g-index

246
all docs

246
docs citations

246
times ranked

8913
citing authors

#	ARTICLE	IF	CITATIONS
1	Contact System: A Vascular Biology Modulator With Anticoagulant, Profibrinolytic, Antiadhesive, and Proinflammatory Attributes. <i>Blood</i> , 1997, 90, 3819-3843.	0.6	538
2	Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1183-1189.	1.9	398
3	Enzymes and Receptors of Prostaglandin Pathways with Arachidonic Acid-derived Versus Eicosapentaenoic Acid-derived Substrates and Products*. <i>Journal of Biological Chemistry</i> , 2007, 282, 22254-22266.	1.6	341
4	The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 28-39.	1.9	298
5	In vivo roles of factor XII. <i>Blood</i> , 2012, 120, 4296-4303.	0.6	285
6	Identification and Characterization of Prolylcarboxypeptidase as an Endothelial Cell Prekallikrein Activator. <i>Journal of Biological Chemistry</i> , 2002, 277, 17962-17969.	1.6	237
7	Use of Factor IX Complex in Warfarin-related Intracranial Hemorrhage. <i>Neurosurgery</i> , 1999, 45, 1113-1119.	0.6	220
8	Prekallikrein Activation and High-Molecular-Weight Kininogen Consumption in Hereditary Angioedema. <i>New England Journal of Medicine</i> , 1983, 308, 1050-1053.	13.9	196
9	Endothelial Kruppel-like factor 4 protects against atherothrombosis in mice. <i>Journal of Clinical Investigation</i> , 2012, 122, 4727-4731.	3.9	180
10	Platelet Aggregation Testing in Platelet-Rich Plasma. <i>American Journal of Clinical Pathology</i> , 2005, 123, 172-183.	0.4	172
11	High Molecular Weight Kininogen Regulates Prekallikrein Assembly and Activation on Endothelial Cells: A Novel Mechanism for Contact Activation. <i>Blood</i> , 1998, 91, 516-528.	0.6	156
12	Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. <i>Blood</i> , 2002, 99, 3585-3596.	0.6	155
13	The plasma kallikrein-kinin system: its evolution from contact activation. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2323-2329.	1.9	153
14	Anti-C5a Ameliorates Coagulation/Fibrinolytic Protein Changes in a Rat Model of Sepsis. <i>American Journal of Pathology</i> , 2002, 160, 1867-1875.	1.9	152
15	Factor XII: What does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis. <i>Thrombosis Research</i> , 2010, 125, 210-215.	0.8	146
16	Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases. <i>Arthritis and Rheumatism</i> , 2000, 43, 1891-1896.	6.7	142
17	Detection of Amide I Signals of Interfacial Proteins in Situ Using SFG. <i>Journal of the American Chemical Society</i> , 2003, 125, 9914-9915.	6.6	140
18	The kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2003, 285, R1-R13.	0.9	138

#	ARTICLE	IF	CITATIONS
19	D-dimer, P-selectin, and microparticles: Novel markers to predict deep venous thrombosis. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1312-1317.	1.8	136
20	Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis. <i>Blood</i> , 2008, 111, 1274-1281.	0.6	136
21	The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. <i>Thrombosis Research</i> , 1984, 33, 51-67.	0.8	134
22	Increased Platelet and Microparticle Activation in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 340-346.	0.9	131
23	Prolylcarboxypeptidase regulates food intake by inactivating $\hat{\pm}$ -MSH in rodents. <i>Journal of Clinical Investigation</i> , 2009, 119, 2291-303.	3.9	122
24	Mapping the Cell Binding Site on High Molecular Weight Kininogen Domain 5. <i>Journal of Biological Chemistry</i> , 1995, 270, 19256-19261.	1.6	118
25	Recombinant prolylcarboxypeptidase activates plasma prekallikrein. <i>Blood</i> , 2004, 103, 4554-4561.	0.6	114
26	Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. <i>Blood</i> , 2001, 97, 2342-2350.	0.6	112
27	Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. <i>Journal of Clinical Investigation</i> , 2014, 124, 2160-2171.	3.9	112
28	SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. <i>EBioMedicine</i> , 2020, 58, 102907.	2.7	110
29	Kallistatin, a novel human tissue kallikrein inhibitor: Levels in body fluids, blood cells, and tissues in health and disease. <i>Translational Research</i> , 1996, 127, 612-620.	2.4	107
30	Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. <i>Blood</i> , 2010, 115, 5111-5120.	0.6	103
31	Factor XII and uPAR upregulate neutrophil functions to influence wound healing. <i>Journal of Clinical Investigation</i> , 2018, 128, 944-959.	3.9	103
32	The elusive physiologic role of Factor XII. <i>Journal of Clinical Investigation</i> , 2008, 118, 3006-9.	3.9	101
33	Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. <i>Blood</i> , 2011, 117, 3929-3937.	0.6	95
34	A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. <i>Urology</i> , 2002, 60, 760-765.	0.5	90
35	The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. <i>Journal of Clinical Investigation</i> , 2002, 109, 1007-1009.	3.9	90
36	Factor XII Does not Initiate Prekallikrein Activation on Endothelial Cells. <i>Thrombosis and Haemostasis</i> , 1998, 80, 74-81.	1.8	89

#	ARTICLE	IF	CITATIONS
37	Thrombotic Microangiopathy in Haematopoietic Stem Cell Transplantation. <i>Drugs</i> , 2009, 69, 183-198.	4.9	89
38	Bradykinin and Its Metabolite, Arg-Pro-Pro-Gly-Phe, Are Selective Inhibitors of $\hat{I}\pm$ -Thrombin-Induced Platelet Activation. <i>Circulation</i> , 1996, 94, 517-528.	1.6	87
39	Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 280, H1821-H1829.	1.5	86
40	Heparan Sulfate Modulates Kinin Release by <i>Trypanosoma cruzi</i> through the Activity of Cruzipain. <i>Journal of Biological Chemistry</i> , 2002, 277, 5875-5881.	1.6	86
41	Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. <i>Blood</i> , 2006, 108, 192-199.	0.6	82
42	Angiotensin 1-7 and Mas decrease thrombosis in <i>Bdkrb2</i> [~] / <i>~</i> mice by increasing NO and prostacyclin to reduce platelet spreading and glycoprotein VI activation. <i>Blood</i> , 2013, 121, 3023-3032.	0.6	80
43	Contact Activation: A Revision. <i>Thrombosis and Haemostasis</i> , 1997, 78, 101-107.	1.8	79
44	Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. <i>International Immunopharmacology</i> , 2008, 8, 161-165.	1.7	78
45	Reduced thrombosis in <i>Klkb1</i> [~] / <i>~</i> mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. <i>Blood</i> , 2015, 125, 710-719.	0.6	76
46	Plasma Prekallikrein: A Risk Marker for Hypertension and Nephropathy in Type 1 Diabetes. <i>Diabetes</i> , 2003, 52, 1215-1221.	0.3	68
47	Ordered adsorption of coagulation factor XII on negatively charged polymer surfaces probed by sum frequency generation vibrational spectroscopy. <i>Analytical and Bioanalytical Chemistry</i> , 2007, 388, 65-72.	1.9	68
48	A Prospective Study of Platelets and Plasma Proteolytic Systems during the Early Stages of Rocky Mountain Spotted Fever. <i>New England Journal of Medicine</i> , 1988, 318, 1021-1028.	13.9	67
49	Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. <i>American Journal of Clinical Pathology</i> , 2005, 123, 172-83.	0.4	66
50	Initiation of Blood Coagulation at Artificial Surfaces. <i>Annals of the New York Academy of Sciences</i> , 1987, 516, 253-267.	1.8	61
51	Protease nexin-2/amyloid \hat{I}^2 -protein precursor in blood is a platelet-specific protein. <i>Biochemical and Biophysical Research Communications</i> , 1991, 175, 15-21.	1.0	61
52	Interaction of Thrombin with PAR1 and PAR4 at the Thrombin Cleavage Site. <i>Biochemistry</i> , 2007, 46, 8603-8610.	1.2	58
53	Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. <i>FEBS Letters</i> , 2002, 523, 167-170.	1.3	57
54	Prolylcarboxypeptidase promotes angiogenesis and vascular repair. <i>Blood</i> , 2013, 122, 1522-1531.	0.6	56

#	ARTICLE	IF	CITATIONS
55	Neonatal purpura fulminans in association with factor V R506Q mutation. <i>Journal of Pediatrics</i> , 1996, 128, 706-709.	0.9	55
56	Assembly and activation of the plasma kallikrein/kinin system: a new interpretation. <i>International Immunopharmacology</i> , 2002, 2, 1841-1849.	1.7	55
57	The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. <i>Journal of Clinical Investigation</i> , 2002, 109, 1007-1009.	3.9	55
58	Genetic polymorphism of the β_2 -adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans. <i>American Journal of Hypertension</i> , 1995, 8, 863-869.	1.0	53
59	Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions. <i>Current Opinion in Hematology</i> , 2000, 7, 261-265.	1.2	53
60	Effect of negatively charged activating compounds on inactivation of factor XIIa by C1 _i , inhibitor. <i>Archives of Biochemistry and Biophysics</i> , 1987, 256, 490-498.	1.4	51
61	Mechanism of Epinephrine-Induced Platelet Aggregation. <i>Hypertension</i> , 1998, 31, 603-607.	1.3	50
62	Myeloperoxidase Interacts with Endothelial Cell-Surface Cytokeratin 1 and Modulates Bradykinin Production by the Plasma Kallikrein-Kinin System. <i>American Journal of Pathology</i> , 2007, 171, 349-360.	1.9	50
63	Physiologic activities of the Contact Activation System. <i>Thrombosis Research</i> , 2014, 133, S41-S44.	0.8	49
64	The contact activation system: Biochemistry and interactions of these surface-mediated defense reactions. <i>Critical Reviews in Oncology/Hematology</i> , 1986, 5, 57-85.	2.0	48
65	Protease Nexin-2/Amyloid β_2 -Protein Precursor Inhibits Factor Xa in the Prothrombinase Complex. <i>Journal of Biological Chemistry</i> , 1995, 270, 23468-23474.	1.6	46
66	Mapping Binding Domains of Kininogens on Endothelial Cell Cytokeratin 1. <i>Journal of Biological Chemistry</i> , 1999, 274, 7137-7145.	1.6	46
67	Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. <i>American Journal of Physiology - Cell Physiology</i> , 2013, 304, C945-C953.	2.1	44
68	Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II. <i>Journal of Molecular Medicine</i> , 2017, 95, 473-486.	1.7	40
69	High Molecular Weight Kininogen Regulates Prekallikrein Assembly and Activation on Endothelial Cells: A Novel Mechanism for Contact Activation. <i>Blood</i> , 1998, 91, 516-528.	0.6	40
70	Activation of the Plasma Kallikrein/Kinin System on Cells: A Revised Hypothesis. <i>Thrombosis and Haemostasis</i> , 1999, 82, 226-233.	1.8	39
71	Expression, purification, and characterization of the Kunitz-type proteinase inhibitor domain of the amyloid β_2 -protein precursor-like protein-2. <i>BBA - Proteins and Proteomics</i> , 1994, 1209, 165-170.	2.1	37
72	Factor IXa Inhibition by Protease Nexin-2/Amyloid β_2 -Protein Precursor on Phospholipid Vesicles and Cell membranes. <i>Biochemistry</i> , 1995, 34, 1171-1178.	1.2	37

#	ARTICLE	IF	CITATIONS
73	A ² PP/APLP2 Family of Kunitz Serine Proteinase Inhibitors Regulate Cerebral Thrombosis. <i>Journal of Neuroscience</i> , 2009, 29, 5666-5670.	1.7	37
74	Mapping the Interaction between High Molecular Mass Kininogen and the Urokinase Plasminogen Activator Receptor. <i>Journal of Biological Chemistry</i> , 2004, 279, 16621-16628.	1.6	34
75	Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 285, H183-H193.	1.5	33
76	Factor V Leiden Inhibits Fibrinolysis In Vivo. <i>Circulation</i> , 2004, 110, 3594-3598.	1.6	32
77	The thromboprotective effect of bortezomib is dependent on the transcription factor Kruppel-like factor 2 (KLF2). <i>Blood</i> , 2014, 123, 3828-3831.	0.6	32
78	Plasma kallikrein activates the epithelial sodium channel in vitro but is not essential for volume retention in nephrotic mice. <i>Acta Physiologica</i> , 2018, 224, e13060.	1.8	32
79	Alpha thalassemia screening in neonates by mean corpuscular volume and mean corpuscular hemoglobin determination. <i>Journal of Pediatrics</i> , 1973, 83, 794-797.	0.9	30
80	The Preparation and Characterization of Novel Peptide Antagonists to Thrombin and Factor VIIa and Activation of Protease-Activated Receptor 1. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 311, 492-501.	1.3	30
81	Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1748-1760.	1.1	30
82	Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations. <i>Journal of Vascular Surgery</i> , 1998, 27, 568-575.	0.6	29
83	Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. <i>Current Opinion in Hematology</i> , 2007, 14, 468-480.	1.2	29
84	The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis. <i>Journal of Endotoxin Research</i> , 2004, 10, 3-13.	2.5	28
85	Plasma kallikrein enhances platelet aggregation response by subthreshold doses of ADP. <i>Biochimie</i> , 2017, 135, 72-81.	1.3	28
86	Factor XII – What's important but not commonly thought about. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 599-606.	1.0	28
87	Activation of the Plasma Kallikrein-Kinin System on Endothelial Cells. <i>Proceedings of the Association of American Physicians</i> , 1999, 111, 220-227.	2.1	28
88	Activation of the plasma kallikrein/kinin system on endothelial cell membranes. <i>Immunopharmacology</i> , 1999, 43, 109-114.	2.0	27
89	Factor XI Assembly and Activation on Human Umbilical Vein Endothelial Cells in Culture. <i>Thrombosis and Haemostasis</i> , 2001, 85, 544-551.	1.8	26
90	The Relative Priority of Prekallikrein and Factors XI/XIa Assembly on Cultured Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 43983-43990.	1.6	25

#	ARTICLE	IF	CITATIONS
91	Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient: insights into structural requirements for kininogen expression. <i>Blood</i> , 2003, 101, 4430-4436.	0.6	24
92	Elevated neutrophil-lymphocyte ratio predicts mortality following elective endovascular aneurysm repair. <i>Journal of Vascular Surgery</i> , 2020, 72, 129-137.	0.6	24
93	Enhanced Plasmin Inhibition by a Reactive Center Lysine Mutant of the Kunitz-type Protease Inhibitor Domain of the Amyloid β -Protein Precursor. <i>Journal of Biological Chemistry</i> , 1995, 270, 22827-22830.	1.6	22
94	The physiologic basis of assembly and activation of the plasma kallikrein/kinin system. <i>Thrombosis and Haemostasis</i> , 2004, 91, 1-3.	1.8	22
95	Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through β 1-integrin and VEGFR2. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 305, H305-H320.	1.5	21
96	Alzheimer disease is in part a thrombohemorrhagic disorder. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 991-994.	1.9	21
97	Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6556.	1.8	21
98	Myeloid-related protein-14 regulates deep vein thrombosis. <i>JCI Insight</i> , 2017, 2, .	2.3	21
99	Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein/kinin and the renin-angiotensin systems. <i>Pharmacological Research</i> , 2020, 160, 105096.	3.1	20
100	Thrombostatin Inhibits Induced Canine Coronary Thrombosis. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1182-1187.	1.8	19
101	Antithrombotic potential of the contact activation pathway. <i>Current Opinion in Hematology</i> , 2016, 23, 445-452.	1.2	19
102	Plasma Prekallikrein: Its Role in Hereditary Angioedema and Health and Disease. <i>Frontiers in Medicine</i> , 2018, 5, 3.	1.2	19
103	Oral thrombostatin FM19 inhibits prostate cancer. <i>Thrombosis and Haemostasis</i> , 2010, 104, 1044-1048.	1.8	18
104	The Williams-Beuren Syndrome—A Window into Genetic Variants Leading to the Development of Cardiovascular Disease. <i>PLoS Genetics</i> , 2012, 8, e1002479.	1.5	18
105	Assessment of whole blood coagulation with a microfluidic dielectric sensor. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2050-2056.	1.9	18
106	Protease Nexin-2/Amyloid β -Protein Precursor Regulates Factor VIIa and the Factor VIIa—Tissue Factor Complex. <i>Thrombosis Research</i> , 2000, 99, 267-276.	0.8	17
107	Prolylcarboxypeptidase Independently Activates Plasma Prekallikrein (Fletcher Factor). <i>Current Molecular Medicine</i> , 2014, 14, 1173-1185.	0.6	17
108	A Novel Antithrombotic Mechanism Mediated by the Receptors of the Kallikrein/Kinin and Renin—Angiotensin Systems. <i>Frontiers in Medicine</i> , 2016, 3, 61.	1.2	16

#	ARTICLE	IF	CITATIONS
109	Ponatinib treatment promotes arterial thrombosis and hyperactive platelets. <i>Blood Advances</i> , 2019, 3, 2312-2316.	2.5	16
110	Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation. <i>Blood Advances</i> , 2021, 5, 4741-4751.	2.5	16
111	Kininogenâ€™Cytokeratin 1 Interactions in Endothelial Cell Biology. <i>Trends in Cardiovascular Medicine</i> , 1999, 9, 238-244.	2.3	15
112	Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury. <i>Cardiovascular Research</i> , 2002, 53, 984-992.	1.8	15
113	Mapping the interaction of bradykinin 1-5 with the exodomain of human protease activated receptor 4. <i>FEBS Letters</i> , 2005, 579, 25-29.	1.3	15
114	Factor XII: New life for an old protein. <i>Thrombosis and Haemostasis</i> , 2010, 104, 915-918.	1.8	15
115	A Cross-sectional Study of KLKB1 and PRCP Polymorphisms in Patient Samples with Cardiovascular Disease. <i>Frontiers in Medicine</i> , 2016, 3, 17.	1.2	15
116	The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release. <i>British Journal of Haematology</i> , 1991, 79, 296-301.	1.2	14
117	Thrombostatin Inhibits Cyclic Flow Variations in Stenosed Canine Coronary Arteries. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1296-1304.	1.8	14
118	Streptococcal inhibitor of complement-mediated lysis (SIC): an anti-inflammatory virulence determinant. <i>Microbiology (United Kingdom)</i> , 2010, 156, 3660-3668.	0.7	14
119	Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab. <i>Clinical Lung Cancer</i> , 2019, 20, e560-e563.	1.1	14
120	Role of the renin-angiotensin system in the development of severe COVID-19 in hypertensive patients. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L596-L602.	1.3	14
121	The hereditary angioedema syndromes. <i>Journal of Clinical Investigation</i> , 2018, 129, 66-68.	3.9	14
122	Left Ventricular Thrombus with Normal Left Ventricular Function and Hyperaggregable Platelets in a Patient with Polycystic Disease of Multiple Organs. <i>American Journal of the Medical Sciences</i> , 1984, 288, 223-227.	0.4	13
123	The Pharmacokinetics of the Kininogens. <i>Thrombosis Research</i> , 1998, 92, 293-297.	0.8	13
124	Transferrin: a blood coagulation modifier. <i>Cell Research</i> , 2020, 30, 101-102.	5.7	13
125	[24] Platelet high-molecular-weight kininogen. <i>Methods in Enzymology</i> , 1989, 169, 276-296.	0.4	12
126	Association of the Prothrombin G20210A Mutation With Factor V Leiden in a Midwestern American Population. <i>American Journal of Clinical Pathology</i> , 2000, 114, 272-275.	0.4	12

#	ARTICLE	IF	CITATIONS
127	Extracorporeal Circulation Without Bleeding. <i>Science Translational Medicine</i> , 2014, 6, 222fs7.	5.8	12
128	Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes. <i>Diabetes</i> , 2016, 65, 498-502.	0.3	12
129	Conformational Changes in Low Molecular Weight Kininogen Alters Its Ability to Bind to Endothelial Cells. <i>Thrombosis and Haemostasis</i> , 1995, 74, 1088-1095.	1.8	12
130	Nomenclature of factor XI and the contact system. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2216-2219.	1.9	11
131	Recombinant Kunitz Protease Inhibitory Domain of the Amyloid β -Protein Precursor as an Anticoagulant in Venovenous Extracorporeal Circulation in Rabbits. <i>Thrombosis and Haemostasis</i> , 1999, 82, 1474-1481.	1.8	11
132	Factor XII Promotes Leukocyte Inflammation and Its Deficiency Results in Faster Wound Healing. <i>Blood</i> , 2011, 118, 368-368.	0.6	11
133	Von Willebrand factor promoter targets the expression of amyloid β protein precursor to brain vascular endothelial cells of transgenic mice. <i>Journal of Alzheimer's Disease</i> , 2003, 5, 149-158.	1.2	9
134	Synthesis of Novel Peptide Inhibitors of Thrombin-induced Platelet Activation. <i>Chemical Biology and Drug Design</i> , 2006, 68, 235-238.	1.5	8
135	Sweet and Sticky. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1548-1550.	1.2	8
136	Quantitation and characterization of human platelet glycoprotein IIIa by radioimmunoassay. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1987, 924, 216-224.	1.1	7
137	Effect of Lanadelumab on Coagulation Parameters in Patients With Hereditary Angioedema: Findings From The Phase 3 HELP Study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, AB41.	1.5	7
138	Modulation of the cell membrane expression of the kininogens regulates the rate of bradykinin delivery to cells. <i>Trends in Cardiovascular Medicine</i> , 1992, 2, 108-114.	2.3	6
139	Gamma Interferon Administration to Patients with Atopic Dermatitis Inhibits Fibrinolysis and Elevates C1 Inhibitor. <i>Thrombosis Research</i> , 1998, 89, 253-261.	0.8	6
140	Laser-light scattering, a new method for continuous monitoring of platelet activation in circulating fluid. <i>Translational Research</i> , 2003, 141, 50-57.	2.4	6
141	Homonymous Hemianopia Caused by Occipital Lobe Infarction in Heparin-Induced Thrombocytopenia and Thrombosis Syndrome. <i>Journal of Neuro-Ophthalmology</i> , 2005, 25, 193-197.	0.4	6
142	Venous and Arterial Thrombosis. , 2014, , 277-296.		6
143	Venous Thromboembolism Chemoprophylaxis in Total Hip and Knee Arthroplasty. <i>JBJS Reviews</i> , 2019, 7, e2-e2.	0.8	6
144	Elevated Neutrophil to Lymphocyte Ratio is Associated with Worse Outcomes after Carotid Endarterectomy in Asymptomatic Patients. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 106120.	0.7	6

#	ARTICLE	IF	CITATIONS
145	Aprotinin: can its benefits be offset by harmful effects?. <i>Transfusion</i> , 1997, 37, 1105-1107.	0.8	5
146	Developing Peptide Inhibitors to Thrombin Activation of Platelets from Bradykinin Analogs. <i>Thrombosis Research</i> , 2001, 104, 451-465.	0.8	5
147	Factor XII gene mutation in the Hageman family. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2329-2331.	1.9	5
148	Short term efficacy of recombinant porcine factor VIII in patients with factor VIII inhibitors. <i>Haemophilia</i> , 2020, 26, 601-606.	1.0	5
149	Are maternal antiplatelet antibodies a prothrombotic condition leading to miscarriage?. <i>Journal of Clinical Investigation</i> , 2011, 121, 4241-4243.	3.9	5
150	Electronically determined red cell indices in a predominantly black urban population of children 4 to 8 years of age. <i>Journal of Pediatrics</i> , 1974, 84, 559-561.	0.9	4
151	Review: The plasma kallikrein/kinin and renin angiotensin systems in blood pressure regulation in sepsis. <i>Journal of Endotoxin Research</i> , 2004, 10, 3-13.	2.5	4
152	A Platelet Acquired Storage Pool Disorder Associated with Tamoxifen Therapy. <i>Case Reports in Hematology</i> , 2012, 2012, 1-3.	0.3	4
153	Vascular Disease Patient Information Page: COVID-19-related thrombosis. <i>Vascular Medicine</i> , 2020, 25, 604-607.	0.8	4
154	Poly (acrylic acid) (PAA) is a contact system activator with properties to stop hemorrhage. <i>Thrombosis Research</i> , 2020, 193, 142-145.	0.8	4
155	Coagulation and Fibrinolysis. , 2011, , 785-800.		4
156	Ponatinib and Cardiovascular Complications. <i>Blood</i> , 2016, 128, 3055-3055.	0.6	4
157	Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2019, 134, 1084-1084.	0.6	4
158	Elevated neutrophil to lymphocyte ratio is associated with decreased amputation-free survival after femoropopliteal percutaneous revascularization. <i>International Angiology</i> , 2021, 40, 442-449.	0.4	4
159	Bradykinin – An elusive peptide in measuring and understanding. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12673.	1.0	4
160	Amyloid Î²-protein precursor: A new anticoagulant?. <i>Translational Research</i> , 1997, 130, 5-7.	2.4	3
161	Thrombosis in flowing blood. <i>Blood</i> , 2009, 114, 754-756.	0.6	3
162	Serpin targets in hemostasis/kinin formation. <i>Blood</i> , 2019, 134, 1566-1568.	0.6	3

#	ARTICLE	IF	CITATIONS
163	Outcomes of Immune Thrombotic Thrombocytopenic Purpura (iTTP) With Upfront Cyclophosphamide vs. Rituximab. <i>Frontiers in Medicine</i> , 2020, 7, 588526.	1.2	3
164	A Novel Point-of-Care Whole Blood Coagulation Assay to Monitor Emicizumab Therapy in Patients with Hemophilia. <i>Blood</i> , 2018, 132, 2475-2475.	0.6	3
165	Vascular Endothelial Cells Produce Coagulation Factors That Control Their Growth via Joint Protease-Activated Receptor and C5a Receptor 1 (CD88) Signaling. <i>American Journal of Pathology</i> , 2022, 192, 361-378.	1.9	3
166	Oscar D. Ratnoff: A man for all seasons. <i>Thrombosis and Haemostasis</i> , 2010, 104, 863-866.	1.8	2
167	Why do we want to know how factor XII levels are modulated?. <i>Thrombosis Research</i> , 2010, 125, 105-106.	0.8	2
168	Transmission of lupus anticoagulant by allogeneic stem cell transplantation. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2014, 36, 287-289.	0.7	2
169	Bilateral, Multiple, Episodic Retinal Vein Occlusions Associated With Common Variable Immunodeficiency. <i>JAMA Ophthalmology</i> , 2015, 133, 1216.	1.4	2
170	Acquired Dysfibrinogenemia Krakow III after Everolimus Therapy. <i>Blood</i> , 2019, 134, 4934-4934.	0.6	2
171	Prolylcarboxypeptidase Promotes Endothelial Cell Proliferation and Vascular Repair. <i>Blood</i> , 2011, 118, 1142-1142.	0.6	2
172	Prolylcarboxypeptidase Murine Hypomorphs Are Hypertensive and Prothrombotic. <i>Blood</i> , 2008, 112, 3915-3915.	0.6	2
173	Neutrophil KLF2 Regulates Arterial and Venous Thrombosis. <i>Blood</i> , 2018, 132, 75-75.	0.6	2
174	Mice Deficient in Å2-Glycoprotein I Have a Delayed Time to Thrombosis. <i>Blood</i> , 2019, 134, 2423-2423.	0.6	2
175	Prekallikrein and Plasma Kallikrein. , 2013, , 2885-2892.		1
176	Coagulation Factor XIIa. , 2013, , 2881-2885.		1
177	Medically-Induced Hemophilia C to Treat Thrombosis. <i>Thrombosis Research</i> , 2015, 136, 185-186.	0.8	1
178	PolyPâ€™s many faces. <i>Blood</i> , 2016, 128, 1669-1670.	0.6	1
179	The amyloid beta-precursor proteinâ€™The unappreciated cerebral anticoagulant. <i>Thrombosis Research</i> , 2017, 155, 149-151.	0.8	1
180	Contact ignition by single-chain XIIa. <i>Blood</i> , 2017, 129, 1411-1412.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Persistent disseminated intravascular coagulation despite correction of endoleaks after thoracoabdominal endovascular aneurysm repair. <i>Journal of Vascular Surgery Cases and Innovative Techniques</i> , 2021, 7, 730-733.	0.3	1
182	The Urokinase Plasminogen Activator Receptor Mediates ScuPA- or FXII-Induced Cell Growth and Proliferation through ERK1/2, Akt, and Beta-1-Integrin.. <i>Blood</i> , 2006, 108, 1817-1817.	0.6	1
183	A Miniaturized Microfluidic Dielectric Sensor for Point-of-Care Assessment of Blood Coagulation. <i>Blood</i> , 2016, 128, 3754-3754.	0.6	1
184	Angiotensin Receptor 2 Over-Expression: A Novel Physiologic Mechanism for Thrombosis Protection.. <i>Blood</i> , 2004, 104, 801-801.	0.6	1
185	Bradykinin B2 Receptor KO Mice Are Protected From Thrombosis by A Platelet Spreading Defect. <i>Blood</i> , 2010, 116, 3198-3198.	0.6	1
186	Exosome Polyphosphate Mediates the Activation of FXII By Cancer Cell-Derived Exosomes. <i>Blood</i> , 2018, 132, 3800-3800.	0.6	1
187	Coagulation Factors. , 2007, , 1-6.		0
188	Coagulation Factor XIIa. , 2007, , 1-14.		0
189	Acute Leukemia. , 2011, , 235-250.		0
190	Thrombosis Prevention without Anticoagulation. <i>Frontiers in Medicine</i> , 2014, 1, 12.	1.2	0
191	Introduction to current issue. <i>Current Opinion in Hematology</i> , 2017, 24, 409-410.	1.2	0
192	Editorial: Introduction to the Presentations at the Factor XI and the Contact System SSC Session of the ISTH, Montpellier, France, May 27, 2016. <i>Frontiers in Medicine</i> , 2017, 4, 140.	1.2	0
193	130: OFF-PUMP CORONARY ARTERY BYPASS IN A PATIENT WITH INHERITED FACTOR V DEFICIENCY. <i>Critical Care Medicine</i> , 2018, 46, 48-48.	0.4	0
194	Editorial: Proceedings of KININ2018CLE, Cleveland, Ohio, June 18-20, 2018: A Compendium of the Presentations. <i>Frontiers in Medicine</i> , 2019, 6, 272.	1.2	0
195	Effect of the Neutrophil/Lymphocyte Ratio on Outcome after Carotid Endarterectomy and Carotid Artery Disease Progression. <i>Journal of the American College of Surgeons</i> , 2020, 231, S343.	0.2	0
196	Case Report: Unmasked Inherited Dysfibrinogenemia After Everolimus Therapy. <i>Frontiers in Medicine</i> , 2020, 7, 591546.	1.2	0
197	Factor XIIâ€™s autoactivation and cell biology interdigitate in disease states. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1808-1812.	1.9	0
198	Mapping the Interaction of Peptide RPPGF with the Exodomain on Human Protease Activated Receptor 4 (PAR4).. <i>Blood</i> , 2004, 104, 1847-1847.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Over-Expression of Prolylcarboxypeptidase Enhances Plasma Prekallikrein Activation on Chinese Hamster Ovary Cell Membranes.. Blood, 2005, 106, 3698-3698.	0.6	0
200	Outside-In Signaling upon Assembly on Endothelial Cells of the Proteins of the Plasma Kallikrein/Kinin System.. Blood, 2005, 106, 1024-1024.	0.6	0
201	The Contributions of the P4-P2 Positions in PAR1 and 4 for Thrombin Recognition and Cleavage.. Blood, 2005, 106, 3574-3574.	0.6	0
202	Kallikrein. , 2007, , 1-15.		0
203	Deletion of Murine Kininogen Gene 1 (mKNG1) Causes Loss of Plasma Kininogen and Delays Thrombosis.. Blood, 2007, 110, 3625-3625.	0.6	0
204	Unique Thrombotic and Hemostatic Complications Associated with Allogeneic Hematopoietic Stem Cell Transplantation. , 2010, , 695-715.		0
205	Prolylcarboxypeptidase Deficiency Is a Risk Factor for Arterial Thrombosis and Hypertension. Blood, 2010, 116, 651-651.	0.6	0
206	Over-Expression of the Mas Receptor Decreases Arterial Thrombosis Risk in B2R KO Mice by Elevating NO and Prostacyclin and Reducing GPVI Activation. Blood, 2011, 118, 700-700.	0.6	0
207	Leukocyte Factor XII Mediates Inflammation and Its Deficiency Promotes Wound Healing. Blood, 2012, 120, 616-616.	0.6	0
208	Discovery of new renal Ang II processing enzyme activity using mass spectrometry and gene deletion mouse models. FASEB Journal, 2013, 27, 1165.18.	0.2	0
209	Thrombosis Protection In Klkb1-/- (Prekallikrein KO) Mice Is Mediated By Increased Renal Mas Receptor, Plasma Prostacyclin, and Aortic Sirt1. Blood, 2013, 122, 195-195.	0.6	0
210	Prolylcarboxypeptidase Is a Risk Factor for Cardiovascular Events. Blood, 2014, 124, 1531-1531.	0.6	0
211	Leukocyte XII Regulates Venous Thrombosis Risk. Blood, 2015, 126, 238-238.	0.6	0
212	Abstract O37: Coagulation Factor XII Promotes Platelet Consumption in the Presence of Microbial Polyphosphate Under Shear Flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	1.1	0
213	Abstract O91: Coagulation Factor XII Promotes Platelet Consumption in the Presence of Microbial Polyphosphate Under Shear Flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, .	1.1	0
214	Physiology of Hemostasis. , 2019, , 81-88.		0
215	Correction to: Concise Guide to Hematology. , 2019, , C1-C1.		0